Clinical Trials Sponsored by ViiV

Total 363 results

ViiV Healthcare

Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections

United Kingdom
ViiV Healthcare

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

HIV Infections

United States
ViiV Healthcare

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOGUE)

HIV Infections | HIV

Spain, Poland, France, Israel, Belgium, Portugal, Germany, Italy, Argentina, Greece, Japan, Ireland, Switzerland, United Kingdom, Denmark, Sweden, Mexico
ViiV Healthcare

Recruiting

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (EBONI)

HIV Infections

United States
ViiV Healthcare

Active, not recruiting

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (EMBRACE)

HIV Infections

United States, Puerto Rico
ViiV Healthcare

Active, not recruiting

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

HIV Infections

Thailand, Kenya, South Africa
ViiV Healthcare

Active, not recruiting

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

HIV Infections

United States, Spain, France, Australia, Germany, Belgium, Canada, Argentina, Brazil, Italy, Romania, Mexico, Taiwan, Netherlands, South Africa, Russian Federation, Greece, Portugal, United Kingdom, Poland, Peru, Chile, Colombia, Ireland and more
ViiV Healthcare

Completed

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

HIV Infections

United States
ViiV Healthcare

Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

HIV Infections

United States
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare

Completed

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

HIV Infections

United States
ViiV Healthcare

Available

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Infection, Human Immunodeficiency Virus
ViiV Healthcare

Completed

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

HIV Infections

United States
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

HIV Infections

United States
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
ViiV Healthcare

Completed

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Puerto Rico, Costa Rica, Panama
ViiV Healthcare

Completed

Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

HIV Infections | Infection, Human Immunodeficiency Virus

China
ViiV Healthcare

Completed

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

HIV Infections

United Kingdom
ViiV Healthcare

Completed

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Infection, Human Immunodeficiency Virus

United States, Spain, Peru, Romania, Colombia, South Africa, Germany, Russian Federation, Argentina, Mexico
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
ViiV Healthcare

Completed

Relative Bioavailability Study of GSK1265744 Formulations

Infections, Human Immunodeficiency Virus and Hepatitis

United States
ViiV Healthcare

Completed

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

HIV Infection

United States
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Not yet recruiting

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

HIV Infections
ViiV Healthcare

Not yet recruiting

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

HIV Infections

United States, Greece, Italy, Argentina, Poland
ViiV Healthcare

Recruiting

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults (CINNAMON)

HIV Infections

United States, France, Italy, Spain, Germany, Canada, Mexico, Argentina, United Kingdom
ViiV Healthcare

Recruiting

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

HIV Infections

United States
ViiV Healthcare

Completed

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Active, not recruiting

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

HIV Infections

United States, Thailand, Brazil, South Africa, Zimbabwe, Botswana, Tanzania
ViiV Healthcare

Completed

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

HIV Infections

United States
ViiV Healthcare

Completed

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

HIV Infections

United States, New Zealand
ViiV Healthcare

Terminated

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (DOMINO)

HIV Infections

Spain, France, United States, Canada, Portugal, Germany, Italy, South Africa, Argentina, Russian Federation, Switzerland
ViiV Healthcare

Completed

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States, Canada, Argentina, Brazil, Mexico, Peru
ViiV Healthcare

Available

Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)

HIV Infections
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Completed

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants (SPAN)

HIV Infections

United States
ViiV Healthcare

Completed

Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254

HIV Infections

United Kingdom
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
ViiV Healthcare

Completed

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

HIV Infections

Spain, France, United States, Germany, Italy, South Africa
ViiV Healthcare

Completed

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Terminated

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Completed

Dolutegravir Pediatric Liquid Formulation Study

HIV Infections

United Kingdom
ViiV Healthcare

Completed

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

HIV Infections

United States
ViiV Healthcare

Completed

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

CHRONIC HEPATITIS B

Iran, Islamic Republic of
ViiV Healthcare

Completed

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

HIV Infections | Infection, Human Immunodeficiency Virus

Russian Federation
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States

3

Subscribe